PHARMACY

New report highlights importance of pharmacists in diabetes management among Canadians

BY Antoinette Alexander

 

TORONTO — As part of Pharmacist Awareness Month, Shoppers Drug Mart and Great-West Life are releasing a new report that demonstrates how pharmacist interventions in diabetes management can make a real impact and improve people's health.

The Sustainable Solutions Report: Pharmacist Interventions in Diabetes shows how pharmacists were able to support diabetes management and influence improvements in health outcomes for participants in a research study, and illustrates how these same benefits could be expanded for all Canadians living with diabetes.

Using the results of a five-minute finger prick blood test (an A1C test), Shoppers Drug Mart pharmacists provided participating Great-West Life plan members with appropriate lifestyle counseling, medication recommendations and, where necessary, physician referrals.  For those patients who returned for a second test, the study found that:
•    The number of patients who reached their target tripled after the first intervention with a Shoppers Drug Mart pharmacist;
•    Approximately half of all patients with a follow-up appointment had a clinically significant reduction in their blood sugar levels;
•    Patients who met their target increased fourfold after the pharmacist consulted with their physician; and
•    Of patients who were not initially at target and received a therapy change, half successfully reached target by their follow-up appointment.

According to researchers, monitoring average blood sugar levels through pharmacist-administered A1C testing can provide important information to assist with optimal diabetes management. The report also includes supporting research where Shoppers Drug Mart pharmacists provided patients with a range of interventions that escalated depending on the severity of the A1C test results. These interventions included discussions on diet, nutrition, exercise and insulin if applicable, adjusting their medication, follow-up appointments or physician referrals.


These results are significant because diabetes rates in Canada are rising fast, impacting not only the health of Canadians, but also placing greater costs and strain on the healthcare system, according to researchers:
•    There were an estimated 2.7 million Canadians living with diabetes in 2010 and that number is expected to rise to 4.2 million by 2020.
•    The cost associated with treating those with diabetes is also significant — it was estimated at $12.2 billion in 2010, and is projected to rise to $16.9 billion by 2020.

Likewise, increasing diabetes rates will cost companies and insurance providers significant amounts in benefits payouts.  Private drug plans spend approximately four times more per capita on prescription drugs for employees with type 2 diabetes than for all other claimants.

Complications from diabetes account for more than 80% of the associated costs of the disease and appropriate interventions by pharmacists can prevent or at least delay those complications, including serious events such as heart attack or stroke.

Recommendations


There is tremendous opportunity to help more Canadians living with diabetes to access care and benefit from these services. The Sustainable Solutions Report: Pharmacist Interventions in Diabetes recommends the following actions:
1.    Expand collaborative opportunities for pharmacists to assess patients' risk of developing diabetes.
2.    Increase scope of practice to allow pharmacists in all provinces to conduct A1C tests for eligible patients and to access test results – allowing even more patients with diabetes to benefit from greater access to health care.
3.    Enable pharmacists to structure and support a plan for patients to self-manage their care through the use of A1C test results and other diabetes assessment tools.
4.    Increase scope of practice to allow pharmacists in all provinces to adapt prescriptions in order to help improve patient outcomes – making it easier for patients to get medication alterations made.
5.    Strengthen opportunities for pharmacist-physician communication and collaboration to better support patients in attaining lifestyle and health outcome goals – especially with respect to their plan of care and any changes in their diabetes-related therapy. 


 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Diplomat Pharmacy sells 7.4 million shares in follow-on offering

BY Michael Johnsen

 

FLINT, Mich. — Diplomat Pharmacy announced Monday that it has commenced its follow-on public offering of 7.4 million shares of its common stock. Diplomat is selling 4.4 million shares of common stock and certain selling shareholders of Diplomat are selling 3 million shares of common stock. The company and selling shareholders intend to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 1.1 million shares of common stock.
 
Diplomat expects to raise approximately $88 million of gross primary proceeds that will be used for debt repayment (under the amended line of credit following the anticipated near-term closing of the BioRx acquisition), working capital and other general corporate purposes, which may include additional debt repayment or future acquisitions. 

The selling shareholders and certain option holders (whose options will be repurchased by the company with additional primary proceeds) will receive the remaining $118 million of gross proceeds expected to be raised in the offering. Diplomat will not receive any proceeds from shares of common stock to be sold by the selling shareholders.
 
Credit Suisse Securities and Morgan Stanley are acting as lead book-running managers. Additional book-running managers are J.P. Morgan Securities and Wells Fargo Securities. William Blair, Leerink Partners and Raymond James are acting as co-managers.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Rexall names new VP pharmacy

BY Antoinette Alexander

MISSISSAUGA, Ontario — Canadian pharmacy retailer Rexall has named Erik Botines as its new VP pharmacy.

In his new role, Botines will lead pharmacy programs and initiatives, pharmacy category management and the development and implementation of professional programs.

Botines has more than 20 years experience in operations, financial management and patient services. Most recently, he held senior management positions at Canada's Shoppers Drug Mart, where he was responsible for pharmacy business development, pricing and patient services.  

Botines spent the first 10 years of his career as an associate franchise owner before making the transition to corporate executive.  
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?